APA (7th ed.) Citation

Lim, J. J., Deng, R., Derby, M. A., Larouche, R., Horn, P., Anderson, M., . . . Tavel, J. A. (2016). Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. Antimicrobial agents and chemotherapy, 60(9), 5437-5444. https://doi.org/10.1128/AAC.00607-16

Chicago Style (17th ed.) Citation

Lim, Jeremy J., et al. "Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers." Antimicrobial Agents and Chemotherapy 60, no. 9 (2016): 5437-5444. https://doi.org/10.1128/AAC.00607-16.

MLA (9th ed.) Citation

Lim, Jeremy J., et al. "Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers." Antimicrobial Agents and Chemotherapy, vol. 60, no. 9, 2016, pp. 5437-5444, https://doi.org/10.1128/AAC.00607-16.